Miura H, Iguchi A, Uemura K, Yatomi A, Tamagawa T, Sakamoto N
Third Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Am J Physiol. 1991 Mar;260(3 Pt 1):E440-6. doi: 10.1152/ajpendo.1991.260.3.E440.
To assess the role of the central nervous system (CNS) in carbohydrate metabolism in diabetes, neostigmine was injected into the third cerebral ventricle in fed rats with streptozotocin (STZ; 80 mg/kg)-induced diabetes under pentobarbital sodium anesthesia. Changes in hepatic venous plasma glucose concentrations were monitored. Neostigmine injection caused no significant changes in the hepatic venous plasma glucose concentration in untreated diabetic rats, whereas the glucose level increased significantly in insulin-treated diabetic rats similarly to the changes in normal control animals. In diabetic rats, the plasma levels of glucagon, epinephrine, and norepinephrine were increased significantly by neostigmine. After various doses (35-80 mg/kg) were given to rats, it was found that the higher the STZ dose, the lower was the hepatic glycogen content and the smaller was the glycemic response to neostigmine. Our results indicate that, in severe diabetes, CNS stimulation with neostigmine fails to increase hepatic glucose output, because glycogen stores are nearly exhausted and gluconeogenesis is already maximal.
为评估中枢神经系统(CNS)在糖尿病碳水化合物代谢中的作用,在戊巴比妥钠麻醉下,将新斯的明注入链脲佐菌素(STZ;80mg/kg)诱导的糖尿病喂食大鼠的第三脑室。监测肝静脉血浆葡萄糖浓度的变化。注射新斯的明对未治疗的糖尿病大鼠肝静脉血浆葡萄糖浓度无显著影响,而胰岛素治疗的糖尿病大鼠血糖水平显著升高,与正常对照动物的变化相似。在糖尿病大鼠中,新斯的明可显著提高胰高血糖素、肾上腺素和去甲肾上腺素的血浆水平。给大鼠注射不同剂量(35 - 80mg/kg)的STZ后,发现STZ剂量越高,肝糖原含量越低,对新斯的明的血糖反应越小。我们的结果表明,在严重糖尿病中,用新斯的明刺激中枢神经系统不能增加肝脏葡萄糖输出,因为糖原储备几乎耗尽,糖异生已经达到最大值。